{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:04:48Z","timestamp":1784653488774,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019535","name":"Texas Tech University Health Sciences Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019535","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.yapd.2025.12.012","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:32:46Z","timestamp":1770669166000},"page":"121-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent Advances in the Management of Type 1 Diabetes in Children"],"prefix":"10.1016","volume":"73","author":[{"given":"Nancy L.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.yapd.2025.12.012_bib1","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJM198605223142106","article-title":"Type I diabetes mellitus. A chronic autoimmune disease","volume":"314","author":"Eisenbarth","year":"1986","journal-title":"N Engl J Med"},{"issue":"9277","key":"10.1016\/j.yapd.2025.12.012_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(01)05415-0","article-title":"Type 1 diabetes: new perspectives on disease pathogenesis and treatment","volume":"358","author":"Atkinson","year":"2001","journal-title":"Lancet"},{"issue":"9911","key":"10.1016\/j.yapd.2025.12.012_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.yapd.2025.12.012_bib4","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine Society, and the American diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.yapd.2025.12.012_bib5","first-page":"S27","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.yapd.2025.12.012_bib6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1210\/clinem\/dgaf267","article-title":"Challenges and opportunities for understanding the pathogenesis of type 1 diabetes: an endocrine Society scientific statement","volume":"110","author":"Michels","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.yapd.2025.12.012_bib7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-021-01418-2","article-title":"100 years of insulin: celebrating the past, present and future of diabetes therapy","volume":"27","author":"Sims","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.012_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1210\/endrev\/bnab010","article-title":"The human islet: mini-organ with mega-impact","volume":"42","author":"Walker","year":"2021","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib9","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/pedi.13410","article-title":"ISPAD clinical practice consensus guidelines 2022: stages of type 1 diabetes in children and adolescents","volume":"23","author":"Besser","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.012_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s40124-025-00351-z","article-title":"Latest updates in prevention and screening of type 1 diabetes mellitus","volume":"13","author":"Citron-Zafrin","year":"2025","journal-title":"Curr Pediatr Rep"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1210\/clinem\/dgaf194","article-title":"Establishing screening programs for presymptomatic type 1 diabetes: practical guidance for diabetes care providers","volume":"110","author":"Leichter","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib12","article-title":"Consensus guidance for monitoring individuals with islet autoantibody\u2013positive pre-stage 3 type 1 diabetes","volume":"47","author":"Phillip","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yapd.2025.12.012_bib13","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/IJGM.S438009","article-title":"Recommendations for screening and monitoring the stages of type 1 diabetes in the immune therapy era","volume":"17","author":"Moore","year":"2024","journal-title":"Int J Gen Med"},{"issue":"12","key":"10.1016\/j.yapd.2025.12.012_bib14","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/clinem\/dgad328","article-title":"Screening and prevention of type 1 diabetes: where are we?","volume":"108","author":"Simmons","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.yapd.2025.12.012_bib15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/dbi20-0054","article-title":"Screening for type 1 diabetes in the general population: a status report and perspective","volume":"71","author":"Sims","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.yapd.2025.12.012_bib16","article-title":"Toward Disease- modifying therapies in type 1 diabetes: focus on Teplizumab","author":"Mathieu","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70120","article-title":"A comprehensive review of novel advances in type 1 diabetes mellitus","volume":"17","author":"Ebrahimpour","year":"2025","journal-title":"J Diabetes"},{"issue":"10","key":"10.1016\/j.yapd.2025.12.012_bib18","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2337\/dc23-0675","article-title":"Teplizumab: a Disease- modifying therapy for type 1 diabetes that preserves \u03b2-Cell function","volume":"46","author":"Herold","year":"2023","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.yapd.2025.12.012_bib19","doi-asserted-by":"crossref","DOI":"10.1007\/s00431-025-06520-y","article-title":"Teplizumab for stage 2 type 1 diabetes: a new era in pediatric diabetes prevention","volume":"184","author":"Zaitoon","year":"2025","journal-title":"Eur J Pediatr"},{"issue":"7","key":"10.1016\/j.yapd.2025.12.012_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An Anti-CD3 antibody, Teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.yapd.2025.12.012_bib23","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and \u03b2-Cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yapd.2025.12.012_bib24","unstructured":"Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-10-20-11-30-00-3169262. Accessed November 2, 2025."},{"issue":"11","key":"10.1016\/j.yapd.2025.12.012_bib25","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.012_bib26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.2337\/dc15-0090","article-title":"Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia","volume":"38","author":"Choudhary","year":"2015","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.yapd.2025.12.012_bib27","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc19-0401","article-title":"Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study","volume":"42","author":"Vantyghem","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.012_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/19382014.2018.1428511","article-title":"The journey of islet cell transplantation and future development","volume":"10","author":"Gamble","year":"2018","journal-title":"Islets"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.012_bib29","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/j.1600-6143.2011.03977.x","article-title":"Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes","volume":"12","author":"Bellin","year":"2012","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.012_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11892-011-0217-8","article-title":"State of the art of clinical islet transplantation and novel protocols of immunosuppression","volume":"11","author":"Shapiro","year":"2011","journal-title":"Curr Diab Rep"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.012_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2014.09.040","article-title":"Generation of functional human pancreatic \u03b2 cells in vitro","volume":"159","author":"Pagliuca","year":"2014","journal-title":"Cell"},{"issue":"7756","key":"10.1016\/j.yapd.2025.12.012_bib32","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-019-1168-5","article-title":"Charting cellular identity during human in vitro \u03b2-cell differentiation","volume":"569","author":"Veres","year":"2019","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib33","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.2337\/db12-1802","article-title":"Improvement in \u03b2-cell secretory capacity after human islet transplantation according to the CIT07 protocol","volume":"62","author":"Rickels","year":"2013","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.yapd.2025.12.012_bib34","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2337\/dc15-1988","article-title":"Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia","volume":"39","author":"Hering","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.yapd.2025.12.012_bib35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJMoa2506549","article-title":"Stem cell-derived, fully differentiated islets for type 1 diabetes","volume":"393","author":"Reichman","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yapd.2025.12.012_bib36","series-title":"Vertex announces positive results from ongoing phase 1\/2 study of VX-880 for the treatment of type 1 diabetes presented at the American Diabetes Association 84th scientific sessions","year":"2024"},{"key":"10.1016\/j.yapd.2025.12.012_bib37","series-title":"Vertex announces positive results for Zimislecel in type 1 diabetes at the American Diabetes Associations 85th scientific sessions","year":"2025"},{"key":"10.1016\/j.yapd.2025.12.012_bib38","series-title":"Presented at: American Diabetes Association","article-title":"Innovation and progress in stem cell-derived islet-cell replacement therapy: durable glycemic control and elimination of exogenous insulin use with VX-880 in patients with type 1 diabetes (T1D) \u2013 VX-880-101 (FORWARD)","author":"Rickels","year":"2025"},{"key":"10.1016\/j.yapd.2025.12.012_bib39","series-title":"Hormone research in paediatrics","first-page":"1","article-title":"Challenges in beta cell replacement for type 1 diabetes","author":"Lemos","year":"2024"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.012_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s43162-025-00477-y","article-title":"Beyond insulin: advancing frontiers in cell-based and genetic therapies for type 1 diabetes management","volume":"37","author":"Addissouky","year":"2025","journal-title":"Egypt J Intern Med"},{"key":"10.1016\/j.yapd.2025.12.012_bib41","series-title":"Pluripotent stem cell therapy for diabetes","article-title":"Islet macroencapsulation: strategies to boost islet graft oxygenation","author":"Ludwig","year":"2023"},{"key":"10.1016\/j.yapd.2025.12.012_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.662084","article-title":"An overview of engineered hydrogel-based biomaterials for improved \u03b2-Cell survival and insulin secretion","volume":"9","author":"Ghasemi","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.yapd.2025.12.012_bib43","doi-asserted-by":"crossref","first-page":"134097","DOI":"10.1016\/j.ijbiomac.2024.134097","article-title":"A comprehensive review on the current status of CRISPR based clinical trials for rare diseases","author":"Kaur Badwal","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.012_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/vaccines12060636","article-title":"Precision in action: the role of clustered regularly interspaced short palindromic repeats\/Cas in gene therapies","volume":"12","author":"Banda","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.yapd.2025.12.012_bib45","article-title":"CRISPR genome editing technology and its application in genetic diseases: a review","volume":"21","author":"Khatibi","year":"2020","journal-title":"Curr Pharm Biotechnol"},{"issue":"29","key":"10.1016\/j.yapd.2025.12.012_bib47","article-title":"CRISPR\/Cas9: the Jedi against the dark empire of diseases","volume":"25","author":"Khan","year":"2018","journal-title":"J Biomed Sci"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1089\/vim.2017.0055","article-title":"Therapeutic strategies of clustered regularly interspaced palindromic repeats-Cas systems for different viral infections","volume":"30","author":"Wahid","year":"2017","journal-title":"Viral Immunol"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.012_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/bfgp\/elaa011","article-title":"CRISPR in medicine: applications and challenges","volume":"19","author":"Sun","year":"2020","journal-title":"Brief Funct Genomics"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.012_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/bfgp\/elw036","article-title":"The applications and advances of CRISPR-Cas9 in medical research","volume":"16","author":"Lu","year":"2017","journal-title":"Brief Funct Genomics"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.012_bib51","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bfgp\/elaa001","article-title":"CRISPR\/Cas9 for cancer treatment: technology, clinical applications and challenges","volume":"19","author":"Cheng","year":"2020","journal-title":"Brief Funct Genomics"},{"key":"10.1016\/j.yapd.2025.12.012_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1369682","article-title":"Era of genomic medicine: a narrative review on CRISPR technology as a potential therapeutic tool for human diseases","volume":"2019","author":"Kotagama","year":"2019","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.012_bib53","first-page":"1","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.012_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s43556-022-00095-y","article-title":"CRISPR\/Cas systems usher in a new era of disease treatment and diagnosis","volume":"3","author":"Li","year":"2022","journal-title":"Mol Biomed"},{"issue":"9","key":"10.1016\/j.yapd.2025.12.012_bib55","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJMoa2503822","article-title":"Survival of transplanted allogeneic beta cells with no immunosuppression","volume":"393","author":"Carlsson","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yapd.2025.12.012_bib56","series-title":"Role of continuous glucose monitoring in diabetes treatment","first-page":"1","article-title":"Introduction: history of glucose monitoring","author":"Hirsch","year":"2018"},{"key":"10.1016\/j.yapd.2025.12.012_bib57","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4093\/dmj.2024.0130","article-title":"Efficacy and safety of automated insulin delivery systems in patients with type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"49","author":"Fan","year":"2025","journal-title":"Diabetes Metab J"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.012_bib58","first-page":"794","article-title":"Reduced burden of diabetes and improved quality of life: experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes","volume":"20","author":"Musolino","year":"2019","journal-title":"Pediatr Diabetes"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.012_bib59","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-022-01465-0","article-title":"Young children with type 1 diabetes: recent advances in behavioral research","volume":"22","author":"Monaghan","year":"2022","journal-title":"Curr Diabetes Rep"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.012_bib61","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/dia.2021.0319","article-title":"Safety and glycemic outcomes during the MiniMed\u2122 advanced hybrid closed-loop system pivotal trial in adolescents and adults with type 1 diabetes","volume":"24","author":"Carlson","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"S3","key":"10.1016\/j.yapd.2025.12.012_bib63","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/dia.2023.0433","article-title":"Celebrating the data from 100,000 real-world users of the MiniMed\u2122 780G system in Europe, Middle East, and Africa collected over 3 years: from data to clinical evidence","volume":"26","author":"Choudhary","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.yapd.2025.12.012_bib65","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2337\/dc21-0172","article-title":"Multicenter trial of a tubeless, On-Body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes","volume":"44","author":"Brown","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.yapd.2025.12.012_bib66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1089\/dia.2023.0578","article-title":"Real-world evidence of omnipod\u00ae 5 automated insulin delivery system use in 69,902 people with type 1 diabetes","volume":"26","author":"Forlenza","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"18","key":"10.1016\/j.yapd.2025.12.012_bib69","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of Closed- loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.yapd.2025.12.012_bib70","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.2337\/dc22-1217","article-title":"Biobehavioral changes following transition to automated insulin delivery: a large real-life database analysis","volume":"45","author":"Kovatchev","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.012_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dia.2020.0535","article-title":"A real-world prospective study of the safety and effectiveness of the loop open source automated insulin delivery system","volume":"23","author":"Lum","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.yapd.2025.12.012_bib73","series-title":"Presented at: American Diabetes Association 85th scientific sessions; Chicago, IL","article-title":"First impressions of the twiist AID system","author":"Mitri","year":"2025"},{"issue":"13","key":"10.1016\/j.yapd.2025.12.012_bib75","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","article-title":"Multicenter, randomized trial of a bionic pancreas in type 1 diabetes","volume":"387","author":"Bionic Pancreas Research Group","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310125000428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065310125000428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:31:14Z","timestamp":1784651474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065310125000428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0065310125000428"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2025.12.012","relation":{},"ISSN":["0065-3101"],"issn-type":[{"value":"0065-3101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in the Management of Type 1 Diabetes in Children","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2025.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}